News
Seeking Alpha on MSN20m
Ionis raises 2025 revenue guidance to $850M with Tryngolza momentum and Donidalorsen launch on trackIonis Pharmaceuticals Q2 2025 earnings highlight strong Tryngolza sales, increased 2025 revenue guidance, and upcoming Donidalorsen FDA approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback